Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery

Journal of Cataract and Refractive Surgery

Volumn 34, Issue 7, 2008, Pages 1114-1120

  Arbisser, Lisa Brothers ^a  

^a Eye Surgeons Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CELL COUNT; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; AZA COMPOUNDS; CATARACT EXTRACTION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INJECTIONS; LENS IMPLANTATION, INTRAOCULAR; MACULA LUTEA; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; QUINOLINES; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 45549095288     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2008.03.017     Document Type: Article

References (36)

1. Barry P., Seal D.V., Gettinby G., Lees F., Peterson M., and Revie C.W. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; preliminary report of principal results from a European multicenter study; the ESCRS Endophthalmitis Study Group. J Cataract Refract Surg 32 (2006) 407-410
2. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 33 (2007) 978-988
3. Montan P.G., Wejde G., Koranyi G., and Rylander M. Prophylactic intracameral cefuroxime; efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg 28 (2002) 977-981
4. Montan P.G., Wejde G., Setterquist H., Rylander M., and Zetterström. Prophylactic intracameral cefuroxime; evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 28 (2002) 982-987
5. Seal D.V., Barry P., Gettinby G., Lees F., Peterson M., Revie C.W., and Wilhelmus K.R. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; case for a European multicenter study; the ESCRS Endophthalmitis Study Group. J Cataract Refract Surg 32 (2006) 396-406
6. Aaberg Jr. T.M., Flynn Jr. H.W., Schiffman J., and Newton J. Nosocomial acute-onset postoperative endophthalmitis survey: a ten-year review of incidence and outcomes. Ophthalmology 105 (1998) 1004-1010
7. Khan R.I., Kennedy S., and Barry P. Incidence of presumed postoperative endophthalmitis in Dublin for a 5-year period (1997-2001). J Cataract Refract Surg 31 (2005) 1575-1581
8. Taban M., Behrens A., Newcomb R.L., Nobe M.Y., Saedi G., Sweet P.M., and McDonnell P.J. Acute endophthalmitis following cataract surgery; a systematic review of the literature. Arch Ophthalmol 123 (2005) 613-620
9. West E.S., Behrens A., McDonnell P.J., Tielsch J.M., and Schein O.D. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 112 (2005) 1388-1394
10. Foster A. Cataract and "Vision 2020-the right to sight" initiative. [editorial]. Br J Ophthalmol 85 (2001) 635-637
11. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study; a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 113 (1995) 1479-1496
12. Speaker M.G., and Menikoff J.A. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 98 (1991) 1769-1775
13. Ciulla T.A., Starr M.B., and Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology 109 (2002) 13-24
14. Ariyasu R.G., Nakamura T., Trousdale M.D., and Smith R.E. Intraoperative bacterial contamination of the aqueous humor. Ophthalmic Surg 24 (1993) 367-373 commentary by J Baum, 373-374
15. Feys J., Emond J.P., Salvanet-Bouccara A., and Dublanchet A. Épidémiologie de la contamination bactérienne oculaire en chirurgie de la cataracte. [Bacterial contamination: epidemiology in cataract surgery]. J Fr Ophtalmol 26 (2003) 255-258
16. Mistlberger A., Ruckhofer J., Raithel E., Müller M., Alzner E., Egger S.F., and Grabner G. Anterior chamber contamination during cataract surgery with intraocular lens implantation. J Cataract Refract Surg 23 (1997) 1064-1069
17. Dickey J.B., Thompson K.D., and Jay W.M. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol 112 (1991) 278-282
18. McDonnell P.J., Taban M., Sarayba M., Rao B., Zhang J., Schiffman R., and Chen Z. Dynamic morphology of clear corneal cataract incisions. Ophthalmology 110 (2003) 2342-2348. http://chen.bli.uci.edu/publications/J50_Ophthalmology2003.pdf.pdf Accessed March 22, 2008
19. Rubio E.F. Influence of age on conjunctival bacteria of patients undergoing cataract surgery. Eye 20 (2006) 447-454
20. Haas M.G., Yung C.-W., Chaluvadi U., and Davis T.E. Vigamox: how good is its self-preservation?. J Cataract Refract Surg 32 (2006) 899-900
21. Gasset A.R., Ishii Y., Kaufman H.E., and Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 78 (1974) 98-105
22. Tripathi B.J., and Tripathi R.C. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res 6 (1989) 395-403
23. Stroman D.W., Dajcs J.J., Cupp G.A., and Schlech B.A. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%; a new topical fluoroquinolone. Surv Ophthalmol 50 suppl (2005) S16-S31
24. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., Romanowski E.G., Mah F.S., Ritterband D.C., and Gordon Y.J. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
25. Kowalski R.P., Yates K.A., Romanowski E.G., Karenchak L.M., Mah F.S., and Gordon Y.J. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112 (2005) 1987-1991
26. Mather R., Karenchak L.M., Romanowski E.G., and Kowalski R.P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
27. McGee D.H., Holt W.F., Kastner P.R., and Rice R.L. Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol 50 suppl 1 (2005) S46-S54
28. Kleinmann G., Larson S., Neuhann I.M., Hunold A., LeBoyer R., Hickman S., Mamalis N., and Olson R.J. Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea 25 (2006) 209-213
29. Ritterband D.C., Shah M.K., Meskin S.W., Shapiro D.E., Seedor J.A., Koplin R.S., Hu D.N., Shao S., Dahl P., and McCormick S. Efficacy and safety of moxifloxacin as an additive in Optisol-GS a preservation medium for corneal donor tissue. Cornea 25 (2006) 1084-1089
30. Gao H., Pennesi M.E., Qiao X., Iyer M.N., Wu S.M., Holz E.R., and Meiler W.F. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci 47 (2006) 1606-1611. http://www.iovs.org/cgi/reprint/47/4/1606 Accessed March 22, 2008
31. Perente I., Utine C.A., Ozturker C., Cakir M., Kaya V., Eren H., Kapran Z., and Yilmaz O.F. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res 32 (2007) 241-247
32. Ching H.-Y., Wong A.C., Wong C.-C., Woo D.C., and Chan C.W. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye 20 (2006) 297-303
33. ® (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 140 (2005) 497-504
34. Kim D.H., Stark W.J., O'Brien T.P., and Dick J.D. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 112 (2005) 1992-1996
35. Espiritu C.R.G., Caparas V.L., and Bolinao J.G. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 33 (2007) 63-68
36. O'Brien T.P., Arshinoff S.A., and Mah F.S. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 33 (2007) 1790-1800